Zevtera, an advanced-generation cephalosporin, is available for treating Staphylococcus aureus bacteremia and 2 other types ...

Basilea Pharmaceutica announces commercial availability of antibiotic Zevtera in United States: Allschwil, Switzerland Wednesday, May 21, 2025, 11:00 Hrs [IST] Basilea Pharmaceuti ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs ...

Merab Dvalishvili has built an impressive name for himself as the bantamweight champion since winning the belt when he ...

A deadly superbug that sometimes claims the lives of more than a million people globally a year may have a nemesis that lives right under your nose.

The story of MRSA begins just four years after methicillin entered medical practice in 1959. The bacteria had already developed resistance to the new antibiotic, demonstrating the remarkable ...

Basilea Pharmaceutica has cited its “stringent risk-return criteria” as a reason for not taking up its option to bring a MRSA antibiotic into clinical development. Basilea secured the license ...

Methicillin-resistant Staphylococcus aureus (MRSA) is a type of staph bacteria that is highly resistant to common antibiotics. Many people carry the MRSA bacteria harmlessly on their skin ...

even under high antibiotic concentrations. When the high methicillin concentrations successfully eliminate wild and even low-resistance MRSA strains, the remaining potentiator mutation-possessing ...

Previous studies have demonstrated that in order to be resistant, MRSA acquires a new cell wall enzyme that allows it to survive exposure to antibiotics. The Sheffield researchers found that this ...

MRSA is an antimicrobial resistance (AMR) superbug that causes over 120,000 deaths per year. Given the urgent need for new, more effective antibiotics and a lack of MRSA vaccines, understanding ...

Scientists have discovered the mechanism which allows the superbug Methicillin Resistant Staphylococcus aureus (MRSA) to become highly resistant to antibiotics, paving the way for new approaches to ...